Dow Up, CytomX Therapeutics Up

All three major indices rose today.

The NASDAQ rose 268.82 points.

The DOW rose 387.94 points.

The S&P rose 67.19 points.

Technology stocks helped lead the market higher, contributing significantly to the broader rally and pushing the NASDAQ to the strongest performance among the three benchmarks. Strength in large-cap growth companies helped lift overall market sentiment and drew renewed investor interest in the tech sector.

The broader market also participated in the advance, with gains across multiple sectors including financials, industrials, and consumer-related companies. The rise in the S&P 500 suggested that buying activity was not limited to a single segment of the market.

Analysts noted that the coordinated gains across the major indices indicate improving investor confidence, even as markets continue to weigh economic data, corporate outlooks, and expectations surrounding monetary policy.

Investors will continue watching upcoming economic reports and corporate developments later this week for further signals about the economy and financial markets' directions.

All this as CytomX Therapeutics rose 2.07 points to end the day at $6.75 per share. The biotechnology company drew strong investor attention after providing a business update and reporting updated Phase 1 data for its oncology candidate varsetamab ravtansine, also known as CX-2051.

The company said the updated clinical results showed encouraging antitumor activity in patients with metastatic colorectal cancer, including confirmed partial responses and a manageable safety profile. The data strengthened investor confidence in the company's pipeline and raised expectations for the program's continued development.

CytomX also highlighted broader progress across its oncology portfolio as part of its corporate update, giving investors a clearer picture of the company's development strategy and upcoming milestones.

Together, the updated clinical data and broader business progress helped drive significant buying interest in CytomX Therapeutics shares during Monday's trading session.